<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: Over the past 2 decades, hematopoietic stem cell transplant has evolved from an experimental procedure to the standard of care, and it is integrated into the management of many diseases </plain></SENT>
<SENT sid="1" pm="."><plain>Hematopoietic stem cell transplant was established at Shiraz University of Medical Sciences in 1993 </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we describe 15 years experience with stem cell transplant at our center in southern Iran </plain></SENT>
<SENT sid="3" pm="."><plain>We provide information on indication, donor type, conditioning chemotherapy regimen, outcome, survival, and long-term follow-up in our stem cell activity </plain></SENT>
<SENT sid="4" pm="."><plain>PATIENTS AND METHODS: From May 1993 to October 2008, 423 patients underwent allogeneic (n=311) and autologous (n=112) stem cell transplants at our center </plain></SENT>
<SENT sid="5" pm="."><plain>For allogeneic stem cell transplant, the conditioning chemotherapy regimen comprised <z:chebi fb="0" ids="28901">busulfan</z:chebi>, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, and antithymocyte globulin for thalassemic patients; <z:chebi fb="0" ids="28901">busulfan</z:chebi> and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> for <z:hpo ids='HP_0001909'>leukemia</z:hpo> patients; and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> and antithymocyte globulin for patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: During this period, 155 B-<z:e sem="disease" ids="C0002875" disease_type="Disease or Syndrome" abbrv="">thalassemia major</z:e> patients (mean age, 9.5 years; range, 2-20 years) underwent allogeneic marrow transplant </plain></SENT>
<SENT sid="7" pm="."><plain>Of 155 patients with a diagnosis of <z:e sem="disease" ids="C0002875" disease_type="Disease or Syndrome" abbrv="">thalassemia major</z:e>, 112 are alive (72%) with full engraftment after a median follow-up of about 8.1 years (range, 12-184 months) </plain></SENT>
<SENT sid="8" pm="."><plain>During this time, 127 <z:hpo ids='HP_0001909'>leukemia</z:hpo> patients including <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (n=68), <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (n=30) and <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (n=29), received allogeneic stem cell transplant </plain></SENT>
<SENT sid="9" pm="."><plain>In this group, long-term, disease-free survival (cure rate) was 67%, 60%, and 62% </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: These data reflect the important role of hematopoietic stem cell transplant in improving survival for a variety of hematopoietic system disorders at our center in Southern Iran </plain></SENT>
<SENT sid="11" pm="."><plain>In patients with B-<z:e sem="disease" ids="C0002875" disease_type="Disease or Syndrome" abbrv="">thalassemia major</z:e> hematopoietic stem cell transplant seems to be the treatment of choice, because it leads to a cure in <z:hpo ids='HP_0000001'>all</z:hpo> classes (Lucarelli risk group, I-III) </plain></SENT>
<SENT sid="12" pm="."><plain>Based on high success rates in patients with class II and III <z:e sem="disease" ids="C0039730" disease_type="Disease or Syndrome" abbrv="">thalassemia</z:e> with the addition of the antithymocyte globulin to conditioning regimen of stem cell transplant, we also recommend using this new method of conditioning in transplant of <z:e sem="disease" ids="C0039730" disease_type="Disease or Syndrome" abbrv="">thalassemia</z:e> patients </plain></SENT>
</text></document>